SCHEMBL6803971

SCHEMBL6803971

N#Cc1cccc(NC(=O)CNc2ccc(N3CCCCC3=O)cc2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.54
RAB9A P51151 3/20 0.54
NPC1 O15118 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
NFKB1 P19838 1/20 0.54
NFKB2 Q00653 1/20 0.54
RELA Q04206 1/20 0.54
MAPT P10636 2/20 0.50
HTT P42858 1/20 0.48
KMT2A Q03164 3/20 0.47
LMNA P02545 3/20 0.47
TSHR P16473 2/20 0.47
HPGD P15428 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.46
GAA P10253 2/20 0.46
PKM P14618 2/20 0.45
TP53 P04637 1/20 0.44
GLA P06280 1/20 0.44
MAPK1 P28482 1/20 0.43
MEN1 O00255 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6807106 0.83 F10 (0.53) ALDH1A1RAB9ANPC1SMN1; SMN2MAPT
SCHEMBL6807557 0.81 F10 (0.63) ALDH1A1RAB9ANPC1SMN1; SMN2MAPT
SCHEMBL5163935 0.79 F10 (0.55) ALDH1A1RAB9ANPC1SMN1; SMN2MAPT
SCHEMBL5164789 0.79 TSHR (0.48) ALDH1A1RAB9ANPC1SMN1; SMN2MAPT
SCHEMBL5163957 0.77 F10 (0.66) ALDH1A1RAB9ANPC1SMN1; SMN2MAPT
SCHEMBL5166228 0.77 F10 (0.53) ALDH1A1RAB9ANPC1SMN1; SMN2KMT2A
SCHEMBL6157604 0.76 F10 (0.47) ALDH1A1RAB9ANPC1SMN1; SMN2MAPT
SCHEMBL6839785 0.76 RAB9A (0.48) ALDH1A1RAB9ANPC1SMN1; SMN2MAPT
SCHEMBL6807934 0.76 MAPT (0.46) ALDH1A1RAB9ANPC1SMN1; SMN2MAPT
SCHEMBL7086320 0.75 ALDH1A1 (0.54) ALDH1A1NPC1SMN1; SMN2MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1524072-A Prenyl-containing derivatives and their use in the treatment of thromboembolic disorders or tumours Ĭ��ר���ɷ����޹�˾ 2004-08-25 CN claimed
US-20040092517-A1 Phenyl derivatives and their use in the treatment of thromboembolic disorders or tumours MERCK PATENT GMBH (DE) 2004-05-13 US claimed
CN-1524072-A Prenyl-containing derivatives and their use in the treatment of thromboembolic disorders or tumours Ĭ��ר���ɷ����޹�˾ 2004-08-25 CN disclosed
US-20040092517-A1 Phenyl derivatives and their use in the treatment of thromboembolic disorders or tumours MERCK PATENT GMBH (DE) 2004-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092517-A1 Phenyl derivatives and their use in the treatment of thromboembolic disorders or tumours RCOR3, F2, NCOR2 ALDH1A1 3576/4885RAB9A 4524/4885NPC1 2490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.